Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: The GLISTEN study - A randomised controlled trial

P.A. Frith, Philip Thompson, R. Ratnavadivel, C.L. Chang, P. Bremner, P. Day, C. Frenzel, N. Kurstjens, A. Waddell, A. Daniel, A. Khoussousi, A. Springfield, A. Veale, A.N. Graham, B. Gallagher, B.R. Pande, B. O'Kane, C. Jones, C. Baldi, C. HelmC. O'Dochartaigh, D. Chambers, D. Quinn, D. Yull, D. Karthigesu, E. Then, F. Graham, F. Faigenbaum, G. Geddam, G. Cameron, H. Blom, H. Goldman, H. Snell, I. Chia, J. Jeong, J. Liew, J. Salvaris, J. Pryke, J. Reid, J. Kolbe, J. O'Sullivan, J. Pak, J. Upham, J. Feiber, J.O.M. Ford, K. Yong, K. Perrin, L. Noonan, L. Atlas, L. Murdoch, M. Pearce, M. Bloch, M. Holmes, M. Chia, M. Epton, M. Leadston, M.K. Tandon, M. Chitgopeker, N. Liebenberg, N. Hendry, O. Olaniyi, O. Singh, P. Kendall, P. Van Niekerk, R. Willet, R. Tomlins, S. Pillay, S. Sharifeh, S. Carson, S. Bingham, T. Walford, T. Erasmus, T. Claridge, Z. Hess

    Research output: Contribution to journal › Article › peer-review

    84 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: The GLISTEN study - A randomised controlled trial'. Together they form a unique fingerprint.

    Pharmacology, Toxicology and Pharmaceutical Science